Altimmune, Inc.
- ALT
- NASDAQ
- Biotechnology
- Obesity Treatments
- Liver Disease (NASH)
$2.23
Today +1.36%Quote Oct 19, 2026, 08:00 PM UTC
−31.38%over the last month
Max drawdown −35.5%From 1-month high −34.6%3 months −20.9%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Altimmune
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
57
Market value
$433.8M
Quote Oct 19
Floor
$2.09
6.3% below price
Resistance
$2.23
Price is above this level
Price vs analyst targets
15 analysts
Lowest target
$2.50Highest target
$10.00
$2.50Highest target
$10.00
- Price $2.23
- Average target $6.25
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 180% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about ALTPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free